Related
Latus Bio Launches with $54 Million to Deliver Gene Therapies Directly to the Brain
Rare Daily Staff Latus Bio, a company developing improved gene therapies that target central nervous system disorders, […]
Read moreAI Used to Identify Undiagnosed Patients with Immune Disorder through EHRs
AI Used to Identify Undiagnosed Patients with Immune Disorder through EHRs Rare Daily Staff Researchers were able […]
Read moreFDA Grants Fast Track to Amolyt’s Experimental Hypoparathyroidism Candidate
Rare Daily Staff The U.S. Food and Drug Administration granted Fast Track designation to Amolyt Pharma’s lead […]
Read moreModerna and Metagenomi End Next-Generation In Vivo Gene Editing Collaboration
Rare Daily Staff Moderna and Metagenomi have agreed to terminate their collaboration to develop next-generation, in vivo […]
Read moreUsing Directed Evolution to Develop New Vectors for Genetic Medicines
Much of the challenge of developing genetic medicines lies in having the right vector to deliver the […]
Read moreAtsena Reports Positive Data from First Cohort of Trial Evaluating Gene Therapy for XLRS
Rare Daily Staff Atsena Therapeutics reported positive preliminary data from the first cohort of the ongoing LIGHTHOUSE […]
Read moreCreyon and Cajal Enter Partnership to Develop ASOs for Neurodegenerative Diseases
Rare Daily Staff Creyon Bio and Cajal Neuroscience have entered a partnership to develop novel antisense oligonucleotide […]
Read moreHarmony Bio Acquires Epygenix, Adding Late-Stage Rare Epilepsy Assets
Rare Daily Staff Harmony Biosciences has acquired Epygenix Therapeutics, accelerating its growth strategy by adding a rare […]
Read moreMustang Bio Raises $4 Million in Public Offering
Rare Daily Staff Mustang Bio, a company focused on cell and gene therapies for difficult-to-treat cancers and […]
Read more